Segall Bryant & Hamill’s Harvard Bioscience HBIO Stock Holding History

Segall Bryant & Hamill’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,919	Closed	-$1.15M	–	849
2018 Q3	$1.15M	Sell	21,919 -75,317	-77%	-$4.23M	0.02%	522
2018 Q2	$5.2M	Sell	97,236 -2,824	-3%	-$145K	0.08%	282
2018 Q1	$5M	Buy	100,060 +16,428	+20%	+$736K	0.12%	196
2017 Q4	$2.76M	Buy	83,632 +7,431	+10%	+$251K	0.06%	271
2017 Q3	$2.86M	Sell	76,201 -1,927	-2%	-$57K	0.07%	272
2017 Q2	$1.99M	Buy	78,128 +43,705	+127%	+$1.08M	0.05%	306
2017 Q1	$895K	Sell	34,423 -2,526	-7%	-$72.8K	0.02%	356
2016 Q4	$1.13M	Buy	36,949 +692	+2%	+$17.6K	0.03%	342
2016 Q3	$986K	Buy	36,257 +2,529	+7%	+$70.2K	0.03%	355
2016 Q2	$965K	Buy	+33,728	New	+$1.07M	0.03%	360

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Segall Bryant & Hamill's HBIO Position: Q4 2018 in Review

Segall Bryant & Hamill sold out of Harvard Bioscience (HBIO) in Q4 2018, closing a stake of 21,919 shares — an estimated $1.15M sold.

Segall Bryant & Hamill first reported a position in HBIO in Q2 2016 and held it in 10 quarters. The position peaked at $5.2M in Q2 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q4 2018.

Segall Bryant & Hamill reported no remaining Harvard Bioscience position as of Q4 2018 after selling out during the quarter.
Segall Bryant & Hamill sold 21,919 Harvard Bioscience shares in Q4 2018, an estimated $1.15M.
Segall Bryant & Hamill first reported a position in Harvard Bioscience in Q2 2016 and held it in 10 quarters.
Segall Bryant & Hamill's Harvard Bioscience position peaked at $5.2M in Q2 2018.
80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2018.

Based on Segall Bryant & Hamill's 13F filing for Q4 2018, filed 15 Feb 2019.